An interventional study of Ferrous sulfate in Obesity, Iron Deficiency and Inflammation, sponsored by Linda Malan. Recruiting at 1 site in South Africa. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by Linda Malan · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Obesity with a site in South Africa — 9 open to participants now, 12 under way, 5 of them phase 3. Obesity · South Africa.
Among the 40 studies in Obesity with a site in South Africa, this one is the 24th largest by planned enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, reaches primary completion later than 5 of the 11 other live ones, and was the 33rd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →9 of the 40 studies in Obesity with a site in South Africa are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in South Africa, United States, Argentina and 16 more countries
Ages 18+
Novo Nordisk A/S · Sites in South Africa, United States, Argentina and 24 more countries
Ages 18+
Brigham and Women's Hospital · Sites in South Africa
Ages 18+
North-West University, South Africa · Sites in South Africa, Switzerland
Ages 5–18 · Healthy volunteers
Sefako Makgatho Health Sciences University · Sites in South Africa
Ages 18+
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 35 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 825 across the 28 interventional studies, 1,231 across the 12 observational. Of the 24 that completed or were terminated, 11 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 40 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Linda Malan as lead sponsor.
Linda Malan has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
1 of the studies in Obesity with a site in South Africa that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07081152Linda MalanIron Absorption and Losses in Young South African Women Living Without and With Overweight and Obesity | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies in Obesity with a site in South Africa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Young women living with obesity (OB) have a greater risk of developing iron deficiency. Plus, the risk of anemia and/or ID in young women living with overweight (OW) and obesity (OB) is further increased by inadequate dietary intake and/or poor bioavailability of iron, as well as gastrointestinal and menstrual iron losses. It is not certain whether women living with OW/OB can meet their iron requirements from their day-to-day diet.
The aim of this study is to compare iron absorption and losses over a long period between women living with and without OW and OB. Secondary outcomes include iron and inflammation status, as well as dietary iron intake.
Adiposity-related inflammation stimulates an increase in secretion of hepcidin hormone thus limiting the absorption of iron and increasing the risk for iron deficiency (ID). In addition, the risk of anemia and/or ID in young women living with overweight (OW) or obesity (OB) is further increased by inadequate dietary intake and/or poor bioavailability of iron, as well as gastrointestinal and menstrual iron losses. Although one study quantified iron losses and absorption in young African women using the stable isotope dilution method the focus was on normal-weight women. Thus, whether women living with OW/OB can meet their iron requirements from their habitual diet remains uncertain.
This is a longitudinal study including an iron absorption study (Phase 1) and a follow-up period (Phase 2) in women living with and without OW and OB.
In phase 1, 70 healthy, mildly- and non-anemic young women living with and without OW or OB will receive a test drink labelled with 15 mg of labelled ferrous sulfate (57Fe) (Visit 1). Fractional iron absorption from the test drink will be determined by measuring the incorporation of the isotopic label into red blood cells 14 days after administration (Visit 2), and will be compared between the two groups. Participants will then undergo a one-year equilibration period. During this time, they will be contacted monthly for an electronically completed, telephonic or in-person health check, chronic medication and supplement use,, blood donation or transfusion, and whether they have fallen pregnant. In addition, they will be asked if they are on a weight-loss diet, a urine pregnancy test done and weight and haemoglobin measured once every 3-4 months. Halfway through the equilibration period we will ask participants not taking hormonal contraceptives (and not intending to do so in phase 2 of the study), to track their menstrual cycle by providing them with a monthly paper- or electronic calendar.
About 1 year after isotope administration, participants will be contacted again and screened (Visit 3) for phase 2 of the study. During this visit, a health and medical history check including the use of proton pump inhibitors,antacids, H2 blockers or iron supplements, contraceptive use and menstruation intensity will be conducted. Then, anthropometric measurements will be performed to determine BMI, and a urine sample collected for pregnancy test. If the participant qualifies to proceed with phase 2, they will be required to consume an antihelminthic dose. Phase 2 of the study will involve 4 visits (Visits 4 to 7), where they will be followed up for 6 months. During this time, blood samples will be drawn every 8 weeks for the determination of isotopic composition. In addition, iron and inflammation status will be assessed. Dietary intake will be assessed using three 24-hour recalls conducted within visits 4, 6 and 7.
Additionally, for willing participants not using hormonal contraceptives and having a regular cycle (26 to 30 days), Visit 4 (or subsequent convenient visit) will be planned to coincide with day 2 of their menstrual phase where 6 ml of blood will be drawn to quantify sex hormones, hepcidin, iron and inflammation status and IL-6. These participants will be invited again during the follicular phase (day 7), early luteal phase (day 18) and late luteal phase (day 23) for additional blood samples. For each of these sampling points, a window period of +/- 1 day will be allowed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional inclusion criteria applicable to phase 2 of the study
Additional exclusion criteria applicable to phase 2 of the study
- Blood transfusion, intravenous iron infusion, blood donation or significant blood loss during the equilibration period
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with body mass index between 18 and 24.9 kg/m2
Other: Ferrous sulfate
Participants with body mass index equal to or greater than 28 kg/m2
Other: Ferrous sulfate
All participants will receive a single dose of 15 mg of iron as isotopically prepared ferrous sulfate labelled with 57Fe. The iron dose will be given with ascorbic acid to attain a molar ratio of ascorbic acid:iron of 2:1
Iron absorption
Long-term iron absorption will be determined in, and compared between women living without and with OW/OB in Phase 2 of the study and will be proportional to the change in the concentration of iron isotope 57 in the erythrocyte over time.
Time frame: Visits 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)
Iron losses
Long-term iron losses will be determined in, and compared between women living without and with OW/OB in Phase 2 of the study and will be proportional to the change in the absolute amount of iron isotope 57 in the erythrocyte over time.
Time frame: Visits 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)
Iron balance
Iron balance will be calculated in and compared between women living without and with OW/OB as the difference between iron absorption and iron losses.
Time frame: Visits 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)
Fractional iron absorption
Fractional iron absorption from a single dose of 15 mg of isotopically-labeled iron will be compared between women living without and with OW/OB.
Time frame: Visit 2 (day 15)
Iron status
Iron status will be determined by measuring plasma ferritin and soluble transferrin receptor.
Time frame: Screening (Ferritin only), Visits 1 (day 1), 4 (day 373), day 378, day 389 and day 394], 5 (day 429), 6 (day 485) and 7 (day 541)
Inflammation status
Inflammation status will be determined by measuring plasma C-reactive protein (CRP) and alpha-1-acid glycoprotein. CRP will also be used to assess the absence or presence of low-grade inflammation at screening for phase 1 and visit 3, using a cut-off of \<2 mg/l and 2-20 mg/l, respectively.
Time frame: Screening (CRP only), Visit 1 (day 1), 3 (day 366;CRP only), day 378, day 389 and day 394] 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)
Dietary iron intake
Dietary iron intake will be assessed using 3 x 24 hr recalls within visits 4, 6 and 7.
Time frame: Visits 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)
Laboratory comparison of measurement of red blood cell isotope concentrations
Iron isotope concentration measurements will be compared between the laboratories at North-West University and the Swiss Federal Institute of Technology Zurich.
Time frame: Visit 2 (day 15), 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)
Dietary intake of iron absorption enhancers
Dietary intake of iron absorption enhancers like vitamin C will be determined using 3 x 24-h recalls questionnaire conducted within the scheduled visit
Time frame: Visits 4 (day 373), 6 (day 485) and 7 (day 541)
Dietary intake of iron absorption inhibitors
Dietary intake of iron absorption inhibitors like phytic acid will be determined using 3 x 24-h recalls questionnaire conducted within the scheduled visit
Time frame: Visits 4 (day 373), 6 (day 485) and 7 (day 541)
Body fat percentage
Body fat percentage will be assessed using the deuterium dilution technique and/or bioelectrical impedance analysis or the bodpod
Time frame: Screening, Visits 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)
Waist circumference
Waist circumference will be measured as an indicator of body fat distribution.
Time frame: Screening, Visits 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)
Hip circumference
Hip circumference will be measured as an indicator of body fat distribution.
Time frame: Screening, Visits 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)
Liver function
Liver function will be assessed by measuring alanine transaminase and aspartate transaminase enzymes.
Time frame: Screening
Gut inflammation
Gut inflammation will be assessed by measuring gut integrity and inflammation biomarkers namely Intestinal fatty acid-binding protein (IFABP) and soluble cluster of differentiation 14 (sCD14).
Time frame: Screening
Menstruation intensity
Menstruation intensity will be assessed using a self-administered health diary
Time frame: Day 373 to day 541
Haemoglobin
Haemoglobin measurement will be compared between a point-of-care device (Hemocue) and an automated haematology analyser
Time frame: Screening
Oestradiol
17-beta oestradiol will be measured on days 2, 7, 18 and 23 of the menstrual cycle. The day 2 sample will align with visit 4 or the next convenient scheduled visit.
Time frame: Visit 4 (day 373), day 378, day 389 and day 394
Progesterone
Progesterone will be measured on days 2, 7, 18 and 23 of the menstrual cycle. The day 2 sample will align with visit 4 or the next convenient scheduled visit.
Time frame: Visit 4 (day 373), day 378, day 389 and day 394
Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 23 months is close to that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.